778 related articles for article (PubMed ID: 30553477)
21. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
Hassan R; Morrow B; Thomas A; Walsh T; Lee MK; Gulsuner S; Gadiraju M; Panou V; Gao S; Mian I; Khan J; Raffeld M; Patel S; Xi L; Wei JS; Hesdorffer M; Zhang J; Calzone K; Desai A; Padiernos E; Alewine C; Schrump DS; Steinberg SM; Kindler HL; King MC; Churpek JE
Proc Natl Acad Sci U S A; 2019 Apr; 116(18):9008-9013. PubMed ID: 30975761
[TBL] [Abstract][Full Text] [Related]
22. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
23. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
24. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
25. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
26. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
28. Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
Urso L; Cavallari I; Sharova E; Ciccarese F; Pasello G; Ciminale V
Br J Cancer; 2020 Jan; 122(1):52-61. PubMed ID: 31819191
[TBL] [Abstract][Full Text] [Related]
29. BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line.
Morrison A; Chekaluk Y; Bacares R; Ladanyi M; Zhang L
PLoS One; 2015; 10(4):e0119224. PubMed ID: 25830670
[TBL] [Abstract][Full Text] [Related]
30. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
31. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
32. KRAS signaling in malignant pleural mesothelioma.
Marazioti A; Krontira AC; Behrend SJ; Giotopoulou GA; Ntaliarda G; Blanquart C; Bayram H; Iliopoulou M; Vreka M; Trassl L; Pepe MAA; Hackl CM; Klotz LV; Weiss SAI; Koch I; Lindner M; Hatz RA; Behr J; Wagner DE; Papadaki H; Antimisiaris SG; Jean D; Deshayes S; Grégoire M; Kayalar Ö; Mortazavi D; Dilege Ş; Tanju S; Erus S; Yavuz Ö; Bulutay P; Fırat P; Psallidas I; Spella M; Giopanou I; Lilis I; Lamort AS; Stathopoulos GT
EMBO Mol Med; 2022 Feb; 14(2):e13631. PubMed ID: 34898002
[TBL] [Abstract][Full Text] [Related]
33. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
34. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
35. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
36. Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Hmeljak J; Sanchez-Vega F; Hoadley KA; Shih J; Stewart C; Heiman D; Tarpey P; Danilova L; Drill E; Gibb EA; Bowlby R; Kanchi R; Osmanbeyoglu HU; Sekido Y; Takeshita J; Newton Y; Graim K; Gupta M; Gay CM; Diao L; Gibbs DL; Thorsson V; Iype L; Kantheti H; Severson DT; Ravegnini G; Desmeules P; Jungbluth AA; Travis WD; Dacic S; Chirieac LR; Galateau-Sallé F; Fujimoto J; Husain AN; Silveira HC; Rusch VW; Rintoul RC; Pass H; Kindler H; Zauderer MG; Kwiatkowski DJ; Bueno R; Tsao AS; Creaney J; Lichtenberg T; Leraas K; Bowen J; ; Felau I; Zenklusen JC; Akbani R; Cherniack AD; Byers LA; Noble MS; Fletcher JA; Robertson AG; Shen R; Aburatani H; Robinson BW; Campbell P; Ladanyi M
Cancer Discov; 2018 Dec; 8(12):1548-1565. PubMed ID: 30322867
[TBL] [Abstract][Full Text] [Related]
37. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
[TBL] [Abstract][Full Text] [Related]
38. Germline BAP1 mutations predispose to malignant mesothelioma.
Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
[TBL] [Abstract][Full Text] [Related]
39. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
[TBL] [Abstract][Full Text] [Related]
40. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
